Investigators enrolled 1,302 asymptomatic women between October 2018 and February 2019; the cohort had a mean age of 37.4 years and represented four northern provinces selected by the University of Health Sciences for collaborator availability. Cervical cytology was evaluable for 1,268 participants after excluding low-quality slides. Using the Anyplex™ II HPV-HR assay, the study team detected at least one high-risk HPV genotype in 256 of 1,184 valid assay results, yielding an overall HR-HPV detection rate of 21.6%. All 14 high-risk types targeted by the kit were observed. The three most frequently detected HR genotypes were HPV 52, HPV 58 and HPV 16, accounting for the plurality of positive detections.
The investigators reported frequent multi-type infections: 100 Anyplex-positive samples contained more than one genotype, and among women with normal cytology 37.3% of HR-HPV–positive samples harboured two or more types. In the subgroup with abnormal cytology (combined with cancer for analysis), HR types detected included 16, 18, 33, 39, 51, 52, 58 and 68; HPV 52 was the most common among those with abnormal cytology (22.2% of HR detections in that group).
The study used two molecular approaches: an in-house GP5+/GP6+ PCR assay and the commercial Anyplex II HR kit. By in-house PCR, 277 of 1,302 samples (21.3%) were positive. Concordance was imperfect: 41 samples were PCR-positive but Anyplex-negative, while 37 samples were Anyplex-positive but PCR-negative. The authors noted that 22 of the Anyplex+/PCR– discordant detections involved HPV 52, indicating assay-specific variation in type detection. Among 118 samples that Anyplex classified as invalid or borderline, some produced positive results by in-house PCR and others negative, underscoring variable assay performance across specimens.
Cytology by the Bethesda System categorized 1,151 of 1,268 evaluable samples (90.8%) as normal and 114 (9.0%) as abnormal; three cases (0.2%) were diagnosed as cervical cancer (squamous cell carcinoma and adenocarcinoma). Of the women with abnormal cytology, 23 samples were positive by both PCR methods, 4 were positive only by Anyplex, and 8 only by in-house PCR. Among women with normal cytology, 234 were PCR-positive and 217 were Anyplex-positive. These results indicate that a substantial portion of HR-HPV infections were detected in women without cytological abnormalities.
The study team catalogued genotype distributions against cytology results: in women with normal cytology the most common HR types were HPV 52, HPV 58, and HPV 16 (14.8%, 9.2%, 7.4% of HR detections respectively). In women with abnormal cytology, the pattern again showed HPV 52 and HPV 58 among the leading types, with HPV 16 and 33 also present; two cancer patients with Anyplex-positive results harboured HPV 16 and HPV 33 respectively.
Bivariate and multivariable regression models incorporated demographic and behavioural covariates such as age, province, ethnicity, occupation, education, marital status, number of sexual partners, vaginal infection history and prior screening. The multivariable analysis indicated that women aged ≥40 years had higher odds of abnormal cytology compared with younger women. Residence in Luangprabang province was independently associated with higher odds of abnormal cytology compared with Huaphan. Marital status also showed an association with HPV detection: women who were single, divorced or widowed had higher odds of being HPV-positive compared with married participants. The article did not provide additional effect estimates beyond those reported for these key variables.
The genotype mix observed in this northern Lao cohort—particularly the prominence of HPV 52 and HPV 58 alongside HPV 16—led the authors to recommend consideration of the nonavalent vaccine, which covers a broader set of oncogenic types than the currently deployed quadrivalent vaccine (types 6, 11, 16 and 18). The manuscript explicitly advised periodic screening for women who are unlikely to have benefited from vaccination introduced in 2020 (school-based quadrivalent program targeting girls aged 10–14). These recommendations derive directly from the local genotype distribution and the documented burden of abnormal cytology within the screened population.
The authors acknowledged several limitations that affect interpretation. Provinces were selected based on collaborator availability rather than by random sampling, which restricts generalisability to the whole country. Some Anyplex assay runs yielded invalid or borderline results (118 samples) and 34 cytology slides were excluded due to low quality, reducing the analyzable denominators. The low absolute number of cancer cases required combining cancer with abnormal cytology for regression analyses. The source did not report additional molecular assay performance metrics such as sensitivity, specificity, or reproducibility beyond the described concordance comparisons. These constraints should temper direct extrapolation of prevalence estimates and inform design considerations for future surveillance or programmatic evaluations.